Second Quarter 2023 Earnings
Forward-Looking Statements.
3
This non-confidential presentation contains forward-looking statements about the business prospects of BioMarin
Pharmaceutical Inc. (Bio Marin), including, without limitation, statements regarding expectations of growth and profitability,
expectations for results of operations and financial guidance for the full-year 2023 and BioMarin's clinical development and
commercial prospects, including, without limitation, (i) the risk of competition and long-lived revenue streams for BioMarin's
enzyme-based therapy products, (ii) the markets for ROCTAVIAN and VOXZOGO, the potential to leverage VOXZO GO in
conditions beyond achondroplasia, such as hypochondroplasia. These forward-looking statements are predictions and
involve risks and uncertainties such that actual results may differ materially from these statements. These risks and
uncertainties include, among others, those factors detailed in BioMarin's press release issued July 31, 2023 and
Bio Marin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under
the caption "Risk Factors" in BioMarin's Annual Report on Form 10-K for the year ended December 31, 2022 as such
factors may be updated by any subsequent reports including BioMarin's Quarterly Report on Form 10-Q for the quarter
ended March 31, 2023. You are urged not to place undue reliance on forward-looking statements, which speak only as of
the date hereof. Bio Marin is under no obligation, and expressly disclaims any obligation to update or alter any forward-
looking statement, whether as a result of new information, future events or otherwise.
BIOMARINView entire presentation